|
Title
|
|
|
|
Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis : a multicenter, open-label trial (TANGO)
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
TANGO Study Group
| |
|
Abstract
|
|
|
|
| Biologic anti-tumor necrosis factor-α (anti-TNF-α) therapies have revolutionized the management of psoriasis. However, despite similar mechanisms of action, inter-patient variability in the clinical responses to therapy remain unexplained. Possible differences between agents include stability or bioavailability and anti-drug antibody development, and patient factors such as compliance may play a role. As a result, it is not uncommon for physicians to switch a patient from one anti-TNF-α agent to another when initial response is inadequate. This multicenter, single-arm, observational, Phase IV study assessed the efficacy and safety of infliximab therapy in patients with moderate-to-severe psoriasis who had not responded to 24 weeks' etanercept treatment. Drug efficacy was assessed using specific psoriasis indexes; health-related quality of life (HRQoL) was measured using the Dermatology Life Quality Index and the Skindex-29. A total of 48 patients were screened, 38 were treated with infliximab and 31 completed the study. Of these, 71% achieved Psoriasis Area and Severity Index 75 after 10 weeks, and improvement in HRQoL was documented. The results of this study showed that patients with moderate-to-severe psoriasis could be successfully switched from etanercept to infliximab, with improvements in both clinical parameter and HRQoL. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The journal of dermatological treatment. - New York
| |
|
Publication
|
|
|
|
New York
:
2015
| |
|
ISSN
|
|
|
|
0954-6634
| |
|
DOI
|
|
|
|
10.3109/09546634.2014.952611
| |
|
Volume/pages
|
|
|
|
26
:4
(2015)
, p. 304-311
| |
|
ISI
|
|
|
|
000361151900002
| |
|
Pubmed ID
|
|
|
|
25231176
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|